The three largest pharmacy benefit managers — or PBMs — earlier this month went to court to quash a suit by the Federal Trade Commission over their pricing practices regarding the diabetes drug insulin.
The three PBMs — CVS Caremark, OptumRx and Express Scripts — are part of even larger health conglomerates that are active in many parts of the health care sector. And the FTC, one of the federal government’s antitrust watchdogs, in September sued, saying the rebates the PBMs extract from drugmakers raise out-of-pocket costs for many of the most vulnerable diabetics. ...
Comments